Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,261 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,261 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00280189 | Study of Outcomes of Radiofrequency Ablation of Lung Tumors | — | suspended | Jan 20, 2006 | University of Pittsburgh | not stated | Not stated |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll… | Phase 1 / Phase 2 | terminated | May 6, 2016 | Cancer Trials Ireland | Accrual lower than anticipated and not expected to improve | Enrollment / accrual |
| NCT04924192 | A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or… | Phase 2 | terminated | Jun 11, 2021 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT06130254 | Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the… | Phase 1 | terminated | Nov 14, 2023 | M.D. Anderson Cancer Center | Sponsor discontinued the trial | Other (stated, no rule matched) |
| NCT04892017 | Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors | Phase 1 | terminated | May 19, 2021 | Deciphera Pharmaceuticals, LLC | Trial terminated due to business decision, not based on any safety or efficacy concerns. | Safety / toxicity |
| NCT06434103 | Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without… | Phase 1 / Phase 2 | withdrawn | May 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor's Strategy Adjustment | Sponsor / business decision |
| NCT02679963 | Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced…(PIPSeN) | Phase 2 | terminated | Feb 11, 2016 | Gustave Roussy, Cancer Campus, Grand Paris | study design, change of standard of care, enrollment difficulties | Enrollment / accrual |
| NCT04908111 | A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1 | Phase 1 / Phase 2 | suspended | Jun 1, 2021 | Cancer Research UK | Sponsor has decided to permanently close recruitment | Enrollment / accrual |
| NCT03348748 | Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage… | Early Phase 1 | terminated | Nov 21, 2017 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT05765734 | A Study of TAS3351 in NSCLC Patients With EGFRmt(TAS3351) | Phase 1 | terminated | Mar 13, 2023 | Taiho Oncology, Inc. | Sponsor's decision, not based on safety concerns | Safety / toxicity |
| NCT06186076 | A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in… | Phase 1 / Phase 2 | terminated | Dec 29, 2023 | Therapex Co., Ltd | Sponsor's decision | Sponsor / business decision |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT04432207 | A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung… | Phase 1 | terminated | Jun 16, 2020 | Imugene Limited | Portfolio prioritization | Sponsor / business decision |
| NCT04911166 | Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small… | Phase 1 | terminated | Jun 2, 2021 | The Methodist Hospital Research Institute | Poor accrual | Enrollment / accrual |
| NCT06580938 | A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People… | Phase 1 | terminated | Aug 30, 2024 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT06599502 | A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and…(ALAFOSS-01) | Phase 1 | terminated | Sep 19, 2024 | AstraZeneca | The decision to cease enrolment and proceed with the early termination of the ALAFOSS 01… | Enrollment / accrual |
| NCT03265496 | Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive…(CONCORDE) | N/A | terminated | Aug 29, 2017 | Centre Oscar Lambret | The number of recruted patient was not sufficient | Other (stated, no rule matched) |
| NCT06083454 | Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Oct 16, 2023 | William Zeitler | funding change | Funding |
| NCT06173505 | Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line… | Phase 1 / Phase 2 | terminated | Dec 15, 2023 | Xencor, Inc. | Business Decision | Sponsor / business decision |
| NCT04832854 | A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus… | Phase 2 | terminated | Apr 6, 2021 | Hoffmann-La Roche | Study was terminated as data became available from Phase 3 trials of perioperative regimens… | Efficacy / futility |
| NCT05636267 | Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | Phase 1 / Phase 2 | terminated | Dec 5, 2022 | Akeso | Terminated due to sponsor strategic development reprioritization. | Sponsor / business decision |
| NCT06219174 | Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC… | Phase 1 / Phase 2 | suspended | Jan 23, 2024 | H. Lee Moffitt Cancer Center and Research Institute | Drugs unavailable | Other (stated, no rule matched) |
| NCT04222972 | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced…(AcceleRET-Lung) | Phase 3 | terminated | Jan 10, 2020 | Hoffmann-La Roche | Early termination of the study resulted from organizational and commercial decisions that led to… | Other (stated, no rule matched) |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT04880382 | Integrative Analysis of Tumor Microenvironment and Optimization of Immunotherapy Duration…(OPTIMUNELUNG) | Phase 2 | terminated | May 10, 2021 | Institut Bergonié | Enrolment was slowlier than expected. | Enrollment / accrual |
| NCT04785287 | Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the… | Phase 1 / Phase 2 | terminated | Mar 5, 2021 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06315296 | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing… | N/A | terminated | Mar 18, 2024 | Thomas Jefferson University | slow accrual | Enrollment / accrual |
| NCT05566223 | CISH Inactivated TILs in the Treatment of NSCLC(CheckCell-2) | Phase 1 / Phase 2 | withdrawn | Oct 4, 2022 | Intima Bioscience, Inc. | No recruitment | Enrollment / accrual |
| NCT06546553 | A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the… | Phase 1 | terminated | Aug 9, 2024 | Pfizer | Study terminated as part of strategic considerations and not based on safety concerns. | Safety / toxicity |
| NCT03066206 | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Phase 2 | terminated | Feb 28, 2017 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03366766 | Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable… | Phase 2 | terminated | Dec 8, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | slow accrual and lack of additional funding | Enrollment / accrual |
| NCT05233436 | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic… | Phase 1 | terminated | Feb 10, 2022 | Pfizer | Study terminated based on internal business considerations and was not based on safety reasons | Safety / toxicity |
| NCT05578092 | A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Phase 1 | terminated | Oct 13, 2022 | Mirati Therapeutics Inc. | business objectives have changed | Sponsor / business decision |
| NCT05462873 | A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With… | Phase 1 | terminated | Jul 18, 2022 | Novartis Pharmaceuticals | Business decision and not related to safety concerns | Safety / toxicity |
| NCT06010355 | Culturally Tailored Educational Video to Promote Lung Cancer Screening in Vulnerable… | N/A | terminated | Aug 24, 2023 | Thomas Jefferson University | Trial is terminated due to lack of staffing | Other (stated, no rule matched) |
| NCT03559049 | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small… | Phase 1 / Phase 2 | terminated | Jun 15, 2018 | University of Michigan Rogel Cancer Center | Due to financial hardships suffered by the stakeholder | Funding |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT05443971 | Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After… | Phase 1 | terminated | Jul 5, 2022 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04081688 | Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC | Phase 1 | terminated | Sep 9, 2019 | Rutgers, The State University of New Jersey | accrual goal met | Enrollment / accrual |
| NCT05488626 | Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer(ARTIA-Lung) | N/A | withdrawn | Aug 4, 2022 | Varian, a Siemens Healthineers Company | Shifting patterns of care for the target population. | Other (stated, no rule matched) |
| NCT04836429 | Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small… | Phase 1 | terminated | Apr 8, 2021 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT06560645 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic… | Phase 1 | terminated | Aug 19, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT06682806 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or… | Phase 2 | terminated | Nov 12, 2024 | Prelude Therapeutics | Sponsor decision | Sponsor / business decision |
| NCT03436056 | PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer…(PRIMING) | Phase 1 | terminated | Feb 19, 2018 | Royal Marsden NHS Foundation Trust | funding pulled | Funding |
| NCT04557007 | Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients(Oncomabs) | — | terminated | Sep 21, 2020 | Oslo University Hospital | Difficulty recruiting | Enrollment / accrual |
| NCT05223647 | Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer(TRIPLEX) | Phase 3 | terminated | Feb 4, 2022 | Norwegian University of Science and Technology | Termination was adviced by Data Safety Committee due to excess toxicity of the experimental… | Safety / toxicity |
| NCT05746481 | Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer… | Phase 2 | terminated | Feb 27, 2023 | Liza Villaruz, MD | Decision by agent provider | Other (stated, no rule matched) |
| NCT02408861 | Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory… | Phase 1 | terminated | Apr 6, 2015 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT05302817 | Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRI | Phase 1 | terminated | Mar 31, 2022 | Xemed LLC | Regulatory compliance. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Apr 14, 2026source: clinicaltrials